The market has learned to turn a child’s suffering into a tradable claim, and this is what remains of a public philosophy that once promised to protect the person from abstraction. In Joshua Pederson’s account for The Guardian, he describes his son’s fight with cancer and argues that Kalshi wants to permit contracts on clinical-trial results and regulatory decisions. A father holding a child through treatment is not a data point. The idea that strangers might profit from the result of that treatment is a moral wound before it is a question of market design.
That is the strongest honest point in Kalshi’s defense. As Pederson reports it, Kalshi chief executive Tarek Mansour argues that drug development is constrained by information and that important evidence can remain locked away from the people who need it. Clinical trials are difficult to understand. Families make decisions under terror, time pressure, and incomplete knowledge. Drug companies have interests. Regulators have limits. Doctors can disagree. A public record that exposed suppressed evidence or institutional complacency could be useful.
But a betting market does not turn power into wisdom merely by putting a price on uncertainty.
The market’s promise is that money will discover the truth. Its actual achievement is to discover what people with money are willing to risk, what information they can access, and what position they believe they can sell before everyone else sees it. A price may summarize expectations. It does not confer judgment, compassion, or responsibility. A contract on a treatment’s success cannot tell a family whether its side effects are bearable, whether a child’s particular case resembles the trial population, or what kind of life the treatment may leave behind.
I know the seduction of abstraction. I traded agricultural futures: paper claims on crops grown by people who had to live with the weather, the soil, and the consequences. The contract was clean. The farm was not. The farther a financial instrument moves from the human practice beneath it, the easier it becomes to call ignorance efficiency.
This is the same movement in medicine. A child becomes an event. A trial becomes a number. A family’s fear becomes volatility. The farther the transaction scales, the more the person disappears. Scale itself erases the particular.
Kalshi’s defenders may say that no trader must hate the child or hope for his death. The contract requires only a view about an outcome. But a system can make a person morally invisible without requiring anyone to feel hatred. That is the deeper danger. The market does not need a villain. It needs only a structure in which one person’s suffering becomes another person’s position.
Pederson reports that Kalshi is not currently allowing bets on treatments for children. That is not a moral defense. It is a temporary boundary around a larger commercial ambition. The relevant question is not only whether children are excluded today. It is who decides where the exclusion ends, and what prevents the boundary from moving once the market has been normalized.
Pederson also reports Kalshi’s interest in contracts tied to flight cancellations. That example matters because it shows the direction of travel: uncertainty itself becomes the product, and every anxiety is invited to become a revenue stream. The danger is not that every contract is equally vile. A canceled flight is not a child’s scan. The danger is the commercial habit that treats both as occasions for monetization, differing only in how much moral resistance the market can overcome.
The father argues for government action to keep such wagers off-limits, Pederson reports, and I understand the impulse. But regulation alone mistakes the symptom for the disease. A rule may forbid a particular contract. It cannot by itself restore the habits and institutions that teach us why the contract should never have been proposed.
Concentrated financial power and concentrated bureaucratic power share a defect: both can make decisions about people while keeping the people affected far from the decision. The state can forbid the bet, and sometimes it should. But a prohibition is not a community. It cannot make a distant executive understand, in his bones, that the line between a sporting event and a child’s PET scan is not a matter of contract design but of the elementary distinction between a person, who is an end, and a commodity, which is a means.
A medical system worthy of the name would give families practical voice, independent counsel, and access to plain-language trial data, while protecting them from the commercial pressure to become consumers of risk. The family is not a passive container into which expertise is poured. The patient and the parents bear the side effects, the uncertainty, and the years that follow. Their knowledge is not a substitute for clinical knowledge. It is part of the knowledge.
This is where the right has forgotten its own inheritance. Hayek’s dispersed knowledge was not a hymn to every price that can be posted on a screen. Oakeshott’s practical knowledge was not an argument for replacing judgment with a ticker. Catholic social teaching does not treat the person as an input awaiting efficient allocation. The earth was given for all, and the goods of creation are ordered toward human flourishing. Property, contract, and exchange have their place. None grants an absolute right to price what another person must endure.
The honest correction must also be made to those who would answer every market abuse with a larger administrative apparatus. A regulator can stop a contract; it cannot supply the thick knowledge of a community. A distant agency can publish a rule; it cannot know which family is carrying the burden of a decision, which nurse has learned a treatment’s hidden cost, or which local institution can hear a frightened parent before fear becomes a statistic. The answer to unaccountable private power cannot be unaccountable public power. Concentration is the problem in both coats.
Nor should the restoration of community be confused with a romantic return to every inherited arrangement. Local institutions can exclude, bully, and protect incumbents. The parish, the family, and the hall deserve loyalty only when they dignify the weak, answer to their members, and survive internal criticism. Tradition is wisdom when it disperses power. It is merely power wearing old clothes when it shields the strong from correction.
The counter-model is therefore not nostalgia. It is patient-governed institution-building.
A patient-governed data trust could require collective consent before clinical information is shared, publish trial outcomes in language families can understand, disclose financial and institutional conflicts, and give patients and caregivers a formal vote over how records are used. Clinicians and researchers would contribute expertise, but they would not own the public record. Families would not merely supply data to a system; they would help govern the system built from it.
Its governing rule would be simple: the people who bear the consequences must have a place in the governance. Its information would be held as a public trust, not traded as an asset. That is not a demand that every medical decision belong to everyone. It is a demand that those who must live with the decision not be reduced to raw material for someone else’s platform.
The same principle applies to prediction markets generally. Kalshi’s flight-cancellation contracts, as Pederson presents them, point toward a world in which every uncertainty is invited to become a wager, every wager becomes a product, and every product claims the moral innocence of information. But information is not innocent when the business model depends on converting human dependency into volume.
I do not blame Pederson for wanting the law to intervene. A father facing his son’s illness is entitled to ask the public to draw a line. The line should be drawn. But the law cannot carry the whole moral burden. A society that has lost the institutions capable of recognizing a person before the market names a price will keep producing new Kalshis, each one discovering a fresh way to call extraction information.
What a child with cancer needs is not only a regulation. He needs a community that cannot imagine betting on him because it knows his name: because his family belongs to a parish, because neighbors can organize help, because a credit union or cooperative can hold a fundraiser, because care is understood as a shared practice rather than a consumer transaction. Those institutions must be open to correction and answerable to the people they serve. They must also be strong enough to carry a conviction that no platform can monetize.
That is the counter-model I trust: the patient council, the public data trust, the accountable medical record, the mutual, the cooperative loan, the local institution that centralizes nothing and leaves no one alone before a distant power. Neither Wall Street nor Washington will make a man’s life sacred. They can protect it, regulate its enemies, and secure the conditions under which neighbors can act. But the conviction that a child is not a wager must be carried by people who know one another well enough to refuse the price.
A clinical trial should be governed as a shared practice ordered toward healing, not as a casino table with a hospital attached. Build the patient council, the public data trust, and the accountable record. Leave the child out of the book.